Cancer

Explore the complexities of Cancer research and treatment in China’s pharmaceutical industry. At Fineline Info & Tech, we provide reliable data, news, and insights to enhance your understanding and decision-making. Stay informed and stay ahead in the fight against cancer with flcube.com.

Company

Tigermed Posts 14% Revenue Growth in 2026 Interim Results – China’s No.1 Clinical CRO Sees Bookings Rebound While Fair‑Value Losses Swing Reported Profit Negative

Hangzhou Tigermed Consulting Co., Ltd. (HKG: 3347, SHE: 300347), China's largest clinical contract research organization (CRO), released its unaudited interim results for the six months ended 30 June 2026. Revenue…

Rainmed Medical Reports 41% Revenue Growth in 2026 Interim Results – caFFR Consumables Drive Gross Margin to 63.2% as Losses Narrow 31%

Rainmed Medical Reports 41% Revenue Growth in 2026 Interim Results – caFFR Consumables Drive Gross Margin to 63.2% as Losses Narrow 31%

China's CDE Slates Highlightll's Ginocitinib (TLL‑018) for Priority Review – First Domestic Dual‑Target JAK1/TYK2 Inhibitor for Rheumatoid Arthritis

China’s CDE Slates Highlightll’s Ginocitinib (TLL‑018) for Priority Review – First Domestic Dual‑Target JAK1/TYK2 Inhibitor for Rheumatoid Arthritis

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDeals

Vela Diagnostics Partners with SRL Inc. to Expand Molecular Diagnostics in Japan

CompanyDrug

Transcenta Secures FDA Approval for Phase III Trial of Osemitamab

CompanyMedical Device

CStone Pharmaceuticals’ PDGFRA Mutation Detection Kit Receives NMPA Approval

CompanyDeals

RemeGen and Akeso Biopharma Initiate Phase II Study for Gastric Cancer Combo Therapy

CompanyDrug

Konruns Pharmaceutical’s KC1036 Pediatric Indication Accepted for NMPA Review

CompanyDrug

Elpiscience Biopharmaceuticals Initiates Phase I Trial for Anti-LILRB2 Antibody ES009

CompanyDrug

Mabwell Bioscience Initiates Phase Ib/II Study for Nectin-4 Targeting ADC 9MW2821

CompanyDrug

BioTroy Therapeutics Receives US FDA IND Approval for Anti-Tumor Drug BT02

Show More